Literature DB >> 6573315

Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male Caucasian volunteers.

R A Yates, H K Adam, R J Donnelly, H L Houghton, E A Charlesworth, E A Laws.   

Abstract

Cefotetan, a third generation cephalosporin, in doses of 0.25, 0.5, 1.0 and 2.0 g was administered intravenously as the disodium salt to ten healthy male Caucasian volunteers and its pharmacokinetics and tolerance determined. The elimination half-life was 3.3 h. The drug was 88% plasma protein bound and 67% was recovered unchanged in the urine. HPLC and bioassay techniques for cefotetan plasma-concentration determinations gave virtually identical results. Cefotetan was well tolerated although half of the volunteers experienced transient mild to moderate diarrhoea. It is concluded that the pharmacokinetic disposition of cefotetan is similar in Caucasian and Japanese subjects and that the long elimination half-life, lack of detectable metabolism and high urinary excretion will result in plasma and urine concentrations in excess of the MIC of sensitive bacteria on a twice daily dosing regime.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6573315     DOI: 10.1093/jac/11.suppl_a.185

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

2.  Quantitative measurement of biliary excretion and of gall bladder concentration of drugs under physiological conditions in man.

Authors:  A Lanzini; M G Pigozzi; A Wuhrer; D Facchinetti; M Castellano; L Bettini; U P Guerra; M Beschi; G Muiesan
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

3.  Pharmacokinetic differences between the epimers of cefotetan disodium after single intravenous injection in healthy Chinese volunteers.

Authors:  Meng-xiang Su; Min-hong Liu; Bin Di; Li-li Huang; Yuan Jiang; Peng-cheng Ma; Tai-jun Hang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-09-14       Impact factor: 2.441

4.  Platelet function and coagulation in patients with hepatobiliary disorders receiving cefotetan prophylaxis.

Authors:  D R Triger; R G Malia; F E Preston
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

5.  Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals.

Authors:  J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

6.  Pharmacokinetics and clinical study of cefotetan in bile: prophylactic use in biliary tract surgery.

Authors:  P Cherrier; P Perrin; S Gueye; A M Bosio; P Tinel; P Blot; R Richer; F Fauvelle
Journal:  Pharm World Sci       Date:  1993-04-23

7.  A simple and sensitive liquid chromatographic technique for the determination of cefotetan disodium in human plasma and its application in a pharmacokinetic study.

Authors:  Yani Liu; Jiangeng Huang; Jinmei Liu; Lin Ma; Yongning Lv; Shaojun Shi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

Review 8.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

9.  Cefotetan pharmacokinetics in volunteers with various degrees of renal function.

Authors:  B R Smith; J L LeFrock; P T Thyrum; B A Doret; C Yeh; G Onesti; A Schwartz; J J Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of cefotetan.

Authors:  C Martin; L Thomachot; J Albanese
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.